| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_218971acc9aab2a35d653ff33bce152b |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate |
1996-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_861f82e8708768e09bf457ff7ece1516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e0f5e4e0d40f1c4bb32e0e4168ccf80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99018e11010cf1a0642403b7e24c4f50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d45087bf0198c03289be407bc403ddba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee46a410b26a92e3be6af881bcb7fa4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a81691e85855a98f7fb9dc776eb8b78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_441ae3780646ca8f10ad8c6083a3dc49 |
| publicationDate |
1998-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H1077298-A |
| titleOfInvention |
Equine interleukin-1 receptor antagonist |
| abstract |
(57) [Summary] [PROBLEMS] To provide a therapeutic agent having no side effect for treating inflammatory diseases such as rheumatoid arthritis in horses. SOLUTION: The therapeutic agent for inflammation of equine, comprising an equine interleukin-1 receptor antagonist having an amino acid sequence shown below and inhibiting the action of equine interleukin-1 as an active ingredient. MEIRRRSVRHLISLLLFLFYSETACHPLGKRPCKMQAFRIWDVNQKTFYM RNNQLVAGYLQESNTKLQEKIDVVPIEPDALFLGLHGRKLCLACVKSGDE IRFQLEAVNITDLSKNKEENKRFTFIRSNSGPTTSFESAACPGWFLCTAQ EADRPVSLTNKPKESFMVTKFYLQEDQ * |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0125435-A3 |
| priorityDate |
1996-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |